Natera, Inc. Commented On The New KDIGO Guideline Supporting Genetic Testing For The Majority Of CKD Patients To Establish Cause Of Disease; Supports Broader Adoption Of Natera's Renasight Test
Portfolio Pulse from Benzinga Newsdesk
Natera, Inc. (NASDAQ:NTRA) has expressed support for the new KDIGO guideline, which recommends genetic testing for most chronic kidney disease (CKD) patients to identify the disease's cause. This guideline aligns with Natera's Renasight test, potentially leading to broader adoption. The guideline's endorsement is based on the RenaCARE study, which showed the diagnostic utility of Renasight in CKD patients. Over 55% of U.S. nephrologists have ordered the Renasight test, indicating significant clinical acceptance.
March 14, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Natera, Inc.'s Renasight test is likely to see broader adoption following the new KDIGO guideline recommending genetic testing for most CKD patients.
The KDIGO guideline's endorsement of genetic testing for CKD diagnosis aligns with Natera's Renasight test, suggesting an increase in its usage. Given that over 55% of U.S. nephrologists have already ordered the test, this guideline could further boost its adoption, potentially impacting Natera's revenues positively in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90